CA-NITRO-SOFTWARE
16.3.2023 01:05:39 CET | Business Wire | Press release
Nitro Software, a global leader in SaaS eSignature and PDF document solutions for businesses, announced today that Nitro Sign was again named a Leader in the GigaOm Radar Report for E-Signature Solutions.
Nitro Sign provides organizations with high-trust electronic signatures that meet or exceed global security and compliance standards, including multiple layers of protection and identity verification. The scalable solution also offers flexible integrations and APIs.
Identifying Nitro Sign as an industry Leader for the second year in a row, GigaOm acknowledged that the Nitro platform supports highly secure, end-to-end digital document processes with a seamless customer experience.
GigaOm’s 2023 Radar Report for E-Signature Solutions awarded Nitro Sign high scores for its:
- extensive compliance support, offering direct eID integration for over 30 jurisdictions
- leading data field configuration and analytics functionality
- best-in-class pricing tiers with minimal add-on fees
- automation and digitization across document workflows
- scalability and security due to its high-trust global data center strategy, extensive security provisions and tamper-proof seals at the signature (rather than envelope) level
GigaOm also noted that Nitro’s broad portfolio can support even the most complex use cases.
“The global adoption of eSignatures took off during the pandemic, and it only continues to accelerate,” said Nitro Chief Product Officer, Sam Thorpe. “Businesses of all sizes, around the world, benefit from the agility, efficiency and productivity eSignature technology enables. And while Nitro delivers a seamless customer experience, as the GigaOm Radar Report attests, there’s far more to our eSignature solutions than just enabling people to sign documents on their devices. Nitro has done the hard work behind the scenes to deliver an easy-to-use, high-trust solution that ensures our customers have the proper security, can avoid fraud and stay compliant.”
GigaOm’s Radar Report notes: “To be a significant player in this space, an e-signature solution must not only support the core e-signature process (preparation, distribution, execution) but also offer extensive compliance support, scalability for high-volume use cases, and flexibility across a range of countries, languages and interfaces. Functionality that simply allows a user to draw a signature on a document is not sufficient to be considered in this report.”
The report adds that “businesses are looking for end-to-end process capabilities rather than standalone solutions. In other words, e-signatures are viewed as a core component of broader document management suites, potentially not something an enterprise would purchase on its own. SMBs will shift more gradually to this strategy but will follow a similar path….”
In its 2023 Radar Report, GigaOm delivers comprehensive evaluations of 14 leading eSignature vendors, an analysis of each of their offerings and provides expert guidance on how to choose the right eSignature vendor for both small and medium business and enterprise requirements.
To read more about Nitro’s position and learn more about what’s happening with eSignatures, click here for a complimentary copy of the GigaOm Radar Report for E-Signature Solutions.
About Nitro Software
Nitro (ASX: NTO) is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its industry-leading analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005670/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom